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Hepatocellular adenoma (HCA) is a rare benign liver tumour associated with the
use of oral contraceptives or other steroid medications which occurs
predominantly in young and middle-aged women. Unlike other benign liver
tumours, an HCA may be complicated by bleeding and malignant
transformation. HCAs have been divided into four subtypes based on molecular
and pathological features: hepatocyte nuclear factor 1α-mutated HCA,
inflammatory HCA, β-catenin-mutated HCA, and unclassified HCA. β-catenin-
mutated HCA has the highest risk of haemorrhage or malignant transformation.
In the latest upgrade of the guidelines regarding the management of benign liver
tumours published in 2016 by the European Association for the Study of the
Liver, magnetic resonance imaging (MRI) was recognized to be superior to all
other imaging modalities in detecting HCAs and in being able to subtype HCAs
up to 80%, with positive identification of 1α-mutated HCA or inflammatory HCA
achievable with > 90% specificity. This review analyzed the imaging features of
HCA using MRI with hepato-specific contrast agents, focusing on the limitations
in the HCA characterization.
Key words: Hepatocellular adenoma; Magnetic resonance imaging; Hepato-specific
contrast media; Liver neoplasm; Gadolinium-ethoxybenzyl-diethylenetriaminepentaacetic
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Core tip: In 2017, a group of French Researchers proposed a new classification of
hepatocellular adenoma based on genomic analysis, identifying three additional
subtypes. However, in this latest paper, the possible imaging features of the
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aforementioned new subtypes of hepatocellular adenoma were not reported. This review
analyzed the imaging features of hepatocellular adenoma using magnetic resonance
imaging with hepato-specific contrast agents, focusing on the limitations of the “old”
imaging criteria proposed by the European Association for the Study of the Liver when
applied to the new subtypes of adenoma.
Citation: Renzulli M, Clemente A, Tovoli F, Cappabianca S, Bolondi L, Golfieri R.





Hepatocellular  adenoma  (HCA)  is  a  benign  hepatic  tumour  which  occurs
predominantly in young and middle-aged women who take oral contraceptives or
other steroid medications[1,2].  The relationship between HCA and the use of  oral
contraceptives was first described by Bühler et al[3], and the incidence of HCA has
been reported to be approximately 30 times greater in oral contraceptive users as
compared to nonusers[1,4]. Moreover, HCA can also be found in patients with glycogen
storage  disease  or  metabolic  syndrome  and  in  men  using  anabolic  steroids[5].
Spontaneous  regression  following  the  withdrawal  of  estrogens  has  also  been
described[3,4,6]. However, the exact role of estrogen in HCA remains elusive[7]. In non-
cirrhotic  patients,  HCA  represents  the  second  most  common  benign  lesion  of
hepatocellular origin after  focal  nodular hyperplasia (FNH) which in turn is  the
second most common liver benign lesion after hemangioma when considering benign
lesions of all origins[8]. However, HCA is a rare tumour, approximately 10 times less
common than FNH[8].
Although  both  FNH  and  HCA  are  benign  lesions,  they  are  managed  quite
differently[9] since, in contrast to FNH, HCA may involve complications, such as life-
threatening bleeding and malignant degeneration[2,10]. In fact, FNH is conservatively
managed in the majority of cases, and resection is not required. Conversely, HCA is
commonly treated with surgical resection due to its serious clinical consequences,
such as spontaneous haemorrhage or malignant transformation[10,11].  Therefore,  a
correct differential diagnosis between FNH and HCA is mandatory but, with state-of-
the-art imaging, this diagnosis is relatively easy to reach by using magnetic resonance
imaging (MRI) with a hepato-specific contrast agent, such as gadoxetic acid[12,13]. In
particular, hyper-/iso-intensity in the hepatobiliary phase of gadoxetic acid MRI is
characteristic and is a prevalent finding of FNH or FNH-like lesions[13,14].
Unfortunately,  the  real  unsolved  problems  of  liver  imaging  still  remain  the
differentiation between HCA and malignant entities[15], and the characterisation of the
different molecular types of HCA[16,17].  In fact,  the different types of HCA have a
different risk of malignant degeneration and, therefore, a correct diagnosis of the
HCA subtype could allow tailored therapy. This review analyses the imaging of HCA,
focusing in particular on the problems which imaging encounters in the diagnosis of
the different molecular subtypes of  HCA when applied to the new classification
proposed by the French Researchers in 2017[17].
HCA AND IMAGING ACCORDING TO THE CURRENT
GUIDELINES
In 2016, the Clinical Practice Guidelines regarding the management of benign liver
tumours  was  published by the  European Association for  the  Study of  the  Liver
(EASL), with a section dedicated to HCA[16]. HCA was divided into four subtypes
according to genomic analysis: Inflammatory HCA (I-HCA) accounting for 30% to
40% of HCAs, hepatocyte nuclear factor 1A mutated HCA (H-HCA) accounting for 40
to 55% of HCAs, β-catenin activated HCA (β-HCA) accounting for 10% to 20% of
HCAs  and  unclassified  HCA  accounting  for  5%  to  10%  of  HCAs.  β-HCA  was
additionally subdivided into two subgroups,  each one constituting 50% of all  β-
HCAs:  exon  3  β-catenin  mutated  and  exon  7-8  β-catenin  mutated.  Finally,  five
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molecular subtypes of HCA were recognizable.
The  molecular  classification  of  HCA  has  markedly  contributed  to  the
understanding of the oncogenic pathways involved in liver tumourigenesis. In fact,
molecular subtyping is highly associated with the risk of malignant transformation
into  hepatocellular  carcinoma (HCC).  Among the  different  subgroups,  β-HCAs
exhibit  the highest risk for malignancy,  including those with dual β-catenin and
inflammatory phenotypes[16].
In many cases, when analyzing the recommended management for a presumed
HCA, a conservative approach is contemplated, for example in a female with a stable
or reduced in size lesion < 5 cm after a 6-mo MRI follow-up. However, whether the
risk of haemorrhage or malignant transformation attributed to β-catenin activation in
HCAs is  independent  of  the  clinical  risk  factors  identified (gender,  size,  rate  of
change) is presently unknown[16]. Therefore, a correct imaging diagnosis is necessary.
HCA  is  no  longer  a  unique  entity,  and  imaging  features  reflect  the  tumour
subtypes. The EASL Guidelines have confirmed the superiority of MRI over all other
imaging modalities in diagnosing HCAs due to its intrinsic properties in fat and
vascular space detection, offering an up to 80% opportunity of subtyping HCAs with
evidence level II-2 and grade of recommendation 1. On MRI, H-HCA is characterized
by  a  diffuse  and  homogeneous  signal  dropout  on  opposed-phase  T1-weighted
sequence,  due  to  the  presence  of  marked  steatosis[16].  I-HCA,  pathologically
characterized by telangiectatic traits,  shows two typical features on MRI[16]:  (1) A
strong hyperintensity on T2-weighted images (as strong as the signal of the spleen),
which may be either diffuse or as a rim-like band in the periphery of the lesion (the
atoll  sign),  especially  in  gross  adenomas;  and (2)  persistent  enhancement  in  the
delayed phase using extracellular MRI contrast agents. Unfortunately, there are no
specific  features  on  MRI  for  the  remaining  types  of  HCA,  such  as  β-HCA  and
unclassified HCA. In summary, the positive identification of H-HCA or I-HCA is
achievable on MRI with > 90% specificity. By contrast, the identification of β-HCA
and its differentiation from unclassified HCA and HCC is not possible using any
imaging techniques, with evidence level II-2 and grade of recommendation 1[16].
NEW PROPOSED CLASSIFICATION OF HCA
In 2017, one year after the release of the updated EASL Clinical Practice Guidelines on
the management of benign liver tumours, an important study by French Authors was
published proposing a new molecular classification of HCA[17]. They confirmed the
five already known subtypes of HCA, but also discovered three new subtypes. The
first two HCAs are mixed tumours in which I-HCA is mixed with β-HCA: one with
the  β-catenin  exon 3  activated subtype  and another  with  the  exon 7,8  activated
subtype.  The  third  one  is  correlated  with  the  activation  of  the  sonic  hedgehog
pathway, sonic hedgehog HCA (shHCA).
Therefore, according to this new proposed classification, eight subtypes of HCA
can be identified: the most common HCAs remain H-HCA (34%) and I-HCA (34%).
The remaining 32% are divided into exon 3 β-catenin mutated HCA (7%), exon 7,8 β-
catenin mutated HCA (3%), the two mixed forms of I-HCA with exon 3 β-HCA (6%)
and exon 7,8 β-HCA (4%), the new entity of sh-HCA resulting from the unclassified
type (4%), and finally unclassified HCA (7%).
Comparing this new classification with the older one, the percentage of H-HCA is
the same as that of I-HCA. Globally, the lesions with β-catenin mutated, in pure form
or in mixed form, are the same. Finally, the percentage of shHCA which derives from
the unclassified type plus unclassified HCA is the same. The same Authors of the new
HCA classification also suggested the possibility of having different tumour subtypes
even within the same liver as a consequence of different deregulated pathways[17]. In
this latest paper[17], the possible imaging features of the aforementioned new subtypes
of  HCA  were  not  reported.  However,  as  a  consequence  of  this  new  HCA
classification, what are the implications for the imaging diagnosis?
IMAGING IMPLICATIONS OF THE NEW HCA
CLASSIFICATION
When applying the imaging criteria of the different subtypes of HCA recognized in
the current version of the EASL Guidelines for the management of benign liver lesions
to the new HCA classification, many considerations should be made.
H-HCA
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H-HCA can be identified by the presence of marked steatosis, resulting from diffuse
and homogeneous signal dropout on chemical shift T1-weighted MRI sequence[16]. The
percentage of this subtype of HCA is the same in the new proposed classification and,
therefore, one-third of HCAs are able to be identified. However, in 2017, other French
Authors from Bordeaux described an atypical form of H-HCA characterized by the
absence of fatty components[18]. Moreover, the Authors declared that four other cases
had been reported which were similar to their observation, either in the context of
mixed liver adenomatosis or HNF1α-inactivated liver adenomatosis[18]. As such, these
HCAs could be categorized as atypical or borderline between HCA and HCC; the
Authors suggested additional studies for a more precise categorization[18]. Therefore,
the presence of signal drop-out on T1-weighted sequences does not allow identifying
all the possible forms of H-HCA (Figure 1) and the absence of signal drop-out on T1-
weighted sequences does not allow excluding the H-HCA diagnosis.  Finally,  the
diagnostic  performance  of  this  MRI  sign  cited  in  the  guidelines  is  drastically
decreased.
Furthermore, many of the same Authors who proposed the new classification of
HCA[17] also published an interesting paper in the same year concerning an atypical
type of HCA[19]. In this paper, they primarily endorsed the importance of the correct
differentiation between the new HCA subtypes due to the different risks of evolution
into HCC[19]. Furthermore, they described an interesting case in which a hepatic lesion
showed  both  the  atoll  sign  and  the  signal  dropout  on  chemical  shift  imaging,
resembling an H-HCA with an inflammatory component. What was it? It was a new
entity, an I-HCA containing fat which introduces a new consideration; even when a
fat containing hepatic lesion is detected on imaging, it could contain an inflammatory
component. Therefore, two limitations in the imaging diagnosis of H-HCAs can be
summarised:  (1)  The  possibility  of  having  an  H-HCA  without  evident  fatty
components; and (2) the fatty components can be identified without excluding the
simultaneous presence of inflammatory components.  As a consequence,  even H-
HCAs  which  make  up  34%  of  HCAs  probably  cannot  be  considered  entirely
diagnosable.
I-HCA–β-HCA-βI-HCA
According to the current EASL Clinical Practice Guidelines, I-HCAs are recognizable
on imaging by two important MRI features: Strong hyperintensity on T2-weighted
images and persistent enhancement on delayed phase images using extracellular MR
contrast agents[16]. Instead, as reported by the EASL Guidelines, the two subtypes of β-
HCA have no characteristic features on MRI and cannot be differentiated from HCC.
βI-HCA  represents  a  mixed  form  of  I-HCA  with  a  β-catenin  component  and,
therefore, this new entity was not able to be diagnosed using MRI due to the absence
of  specific  features  for  the  β-catenin  component.  Probably,  these  mixed  lesions
demonstrate  the  MRI  pattern  of  I-HCA.  This  aspect  presents  a  huge  diagnostic
problem: how is it possible to correctly diagnose an I-HCA and, therefore, to exclude
the possibility that it is not a βI-HCA (Figure 2)? As a consequence, when considering
the sum of the rates of these three types of HCA (I-HCA – β-HCA - βI-HCA, 54%),
they probably cannot be considered diagnosable.
sh-HCA–Unclassified HCA
According to the current EASL Clinical Practice Guidelines, unclassified HCAs have
no  characteristic  features  on  MRI  and  cannot  be  differentiated  from  HCC[16].
Consequently,  sh-HCA,  previously  considered  an  unclassified  form,  is  not
diagnosable by imaging.
DISCUSSION
The guidelines commonly used in current clinical practice regarding the management
of benign liver tumours, such as HCAs, were recently published in 2016 by EASL[16].
These guidelines have pointed out the superiority of MRI as compared to all other
imaging modalities in diagnosing HCA and its opportunity of subtyping HCAs up to
80%. In particular, the differential diagnosis between H-HCA and I-HCA is possible
using  MRI,  having  a  sensitivity  of  87%-91%  and  a  specificity  of  89%-100%  in
diagnosing H-HCAs and a sensitivity of 85%-88% and a specificity of 88%-100% for I-
HCA diagnosis. By contrast, the EASL guidelines stated that the identification of β-
HCA and its differentiation from unclassified HCA and HCC is not possible by any
imaging technique. As H-HCAs and I-HCAs make up a total of 95% of all HCAs, the
current  knowledge regarding MRI should allow diagnosing the vast  majority of
HCAs.
However, considering the new proposed classification of HCAs and its clinical
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Figure 1
Figure 1  Diagnostic challenges in hepatocyte nuclear factor 1A mutated hepatocellular adenoma. A: In a 51-year-old woman, the axial T1 in-phase image
shows an isointense lesion in liver segment V; B: With signal dropout in the T1 out-of-phase image; C: Slightly hyperintense in the T2-weighted; D: In diffusion-
weighted; E: In the arterial phase images; F: Washout of the contrast media in the portal-venous phase; G: In the delayed phase images; H: Hypointense in the
hepatobiliary phase image. According to the current guidelines, this lesion is suggestive for a hepatocellular adenoma inactivated for HNF-1α. However, according to
the newer proposed classification of hepatocellular adenoma, it is not possible to exclude an inflammatory hepatocellular adenoma containing fat and, as
consequence, even a mixed form of β-catenin activated-inflammatory hepatocellular adenoma, on imaging.
implications[17] and, according to the considerations expressed in the previous section,
none of the HCA subtypes could be correctly identifiable. Even for the same H-HCAs
and I-HCAs, which could previously be diagnosed with high reliability, MRI does no
longer provides the same diagnostic accuracy. Therefore, while molecular typing is
evolving towards a more specific characterization of HCAs, the imaging reliability in
the  detection  of  the  various  molecular  subtypes  is  not  proceeding  in  the  same
direction. In fact, in 2016, it was possible to diagnose two out of the four types of HCA
which together represented the vast majority of HCAs and, after only one year, it was
not possible to obtain a certain diagnosis in the vast majority of HCAs according to
the more recent classification.
For this reason, the imaging diagnosis of HCA has become a sticking point: what
should the imaging approach for diagnosing HCA be in current clinical practice? As is
well known, HCA is a rare benign lesion; however, atypical, indeterminate lesions
detected by other imaging techniques such as ultrasound or computed tomography
are rather frequent in clinical practice and, in the opinion of the Authors, the first step
in these cases remains a correct differential diagnosis between benign and malignant
liver lesions. For example, in a non-cirrhotic liver, strong enhancement on the arterial
phase  images  and  hyper-  or  iso-intensity  in  the  hepatobiliary  phase  images  of
gadoxetic acid MRI is helpful in diagnosing FNH and differentiating it from other
lesions  such  as  HCA,  with  a  sensitivity  and  specificity  of  83.8%  and  98.5%,
respectively[20]. Unlike FNH, HCAs appear hypointense in the hepatobiliary phase due
to the reduction in the OATP1 or similar membrane carrier expressions, such as in the
de-differentiation process of regenerative nodules in a cirrhotic liver, permitting an
imaging  diagnosis  with  a  sensitivity  and  specificity  of  83.7%  and  100%,
respectively[11,21-24]. The combination of low signal intensity in the hepatobiliary phase
with  routine  MRI  features  and  risk  factors  of  liver  disease,  could  substantially
improve the diagnosis of HCAs[24]. In addition, MRI performed with gadoxetic acid
was demonstrated to be the most cost-effective strategy for differentiating FNH from
HCA in patients  with  incidentally  detected focal  liver  lesions  in  a  non-cirrhotic
liver[25,26].
However, in cases in which there is a diagnosis of HCA, is it possible to reach a
correct  diagnosis  regarding  the  type  of  HCA  according  to  the  most  recent
classification[17]? Consequent to the previously expressed considerations, the answer is
no. Therefore, what should the diagnostic approach be, in current clinical practice, for
a lesion suspected of being an HCA? The Authors believe that the signal dropout on
opposed T1-weighted images on MRI can be pathognomonic of H-HCA only when
the entire lesion shows homogeneous steatosis. Moreover, when using this imaging
features  it  is  not  possible  to  diagnose  all  H-HCA as  HCAs  without  steatosis[18].
Therefore, a good percentage of but not all H-HCAs which globally represent only
30% of all HCAs are able to be diagnosed.
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Figure 2
Figure 2  Diagnostic challenges in the imaging classification of hepatocellular adenoma. A: In a 47-year-old woman the axial T1 in-phase; B: Out-of-phase
images show an isointense lesion in liver segment V; C: Hyperintense in the T2-weighted; D: In the diffusion-weighted; E: In the arterial phase images; F: Without
washout of the contrast media in the portal-venous phase; G: In the delayed phase images; H: Hypointense in the hepatobiliary phase image. According to the current
guidelines, this lesion is suggestive for an inflammatory hepatocellular adenoma. However, it is not possible to exclude a mixed form of β-catenin activated-
inflammatory hepatocellular adenoma or even a hepatocellular adenoma inactivated for HNF-1α without fatty component.
For the remaining non-diagnosable H-HCAs and for the remaining types of HCA
for which there are no specific imaging features, the only diagnostic strategy currently
available  is  a  biopsy[16].  However,  the  same Authors  of  the  new classification of
HCAs[16] pointed out the intra-tumoural heterogeneity of HCAs. For these reasons,
how many biopsy  would  be  needed for  a  single  lesion?  Furthermore,  the  same
Authors described the inter-tumoural heterogeneity of HCAs, characterized by the
presence of different molecular subtypes within the same liver[17]. How many lesions
is it necessary to biopsy in order to reach a diagnosis? Therefore, it is evident that
even biopsy does not represent the solution for managing the new HCA subtypes.
Surely, the size of a presumed HCA is an important imaging feature because it is
usually correlated with a high risk of haemorrhage, especially for exophytic lesions,
irrespective of the molecular HCA subtype. In particular, an HCA greater than 5 cm
or increasing in size (> 20% in 6 mo) should be considered for resection or curative
treatment[16]. Patient gender has an importance influence on lesion management since
a significantly higher incidence of  malignant  transformation is  reported in men,
regardless of the lesion size[27].  However, the EASL Guidelines have reported that
“Whether the risk of haemorrhage or malignant transformation attributed to β-HCA
is independent  of  the identified clinical  risk factors  (sex,  size,  rate  of  change)  is
presently unknown”. This is still another open question!
What  is  the  future  scenario  of  HCA  imaging?  Some  Authors  have  recently
compared the behaviour regarding diffusion-weighted images of MRI among the
different HCA types. They have revealed different apparent diffusion coefficient
values among the HCA types, the lowest being for β-HCA, and they therefore found
that  the  apparent  diffusion  coefficient  value  is  a  potential  marker  of  malignant
transformation[28]. Obviously, future studies are needed to validate or to redefine these
data permitting an imaging diagnosis for almost all HCA types with a high rate of
malignant degeneration.
CONCLUSION
While awaiting novelties regarding the imaging diagnosis of the new types of HCA, it
is  necessary to  draw up precise  and newer guidelines  with respect  to  the  EASL
guidelines in order to establish the correct and univocal management of the new HCA
entities to be adopted into current clinical practice.
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